April 2, 2024
Teva Takeda Pharma said on April 1 that it has taken over the Japanese marketing authorization (MA) of multiple sclerosis treatment Copaxone (glatiramer) from Takeda Pharmaceutical, effective the same day. The MA transfer wraps up transactions provided under the two...read more